Recent executive movements at Biogen

William Hawkins will join the company as Director on Jun. 19, 2019  (news posted on April 29 2019).
Jesus Mantas will join the company as Director on Jun. 19, 2019  (news posted on April 29 2019).
Jesus Mantas will join the company as Director on Jun. 19, 2019  (news posted on April 29 2019).

Click here to view some more movements at Biogen

Create an alert
to follow the executive moves at Biogen.

Latest M&A news in Biotechnology.

Castle Creek Pharmaceuticals has announced the acquisition of Fibrocell Science (posted on Sep 13, 2019).
Medicine Man Technologies has announced the acquisition of MedPharm (posted on Sep 12, 2019).
Vertex Pharmaceuticals has announced the acquisition of Semma Therapeutics (posted on Sep 4, 2019).

Biogen is one of the...

• Forbes Global 2000;
• Fortune 500;
• Nasdaq 100;
• Russell 3000;
• S&P 500.

Most searched biographies at Biogen

• Michel Vounatsos, Chief Executive Officer & Director
• Stelios Papadopoulos, Chairman of the Board
• Lynn Schenk, Director

Click on an executive to view his biography >

Other contacts in the Biotechnology industry

• Fred Cohen - Director at UroGen
• Sylke Hassel - Senior Vice President and Global Head of Mammalian Busines at Lonza
• Catherine Courboillet - Chief Executive Officer at Cerba Healthcare

Learn more about the Biotechnology industry >

Latest news about Biogen

Biogen and Eisai Announce Presentation of Detailed Analyses from the Phase 1b Long-Term Extension Study of Aducanumab at Clinical Trials on Alzheimer’s Disease (CTAD) | Biogen
Eisai and Biogen Announce Presentation of Additional Data From the Phase II Clinical Trial of BAN2401 in Early Alzheimer’s Disease at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Conference | Biogen
UCB and Biogen Announce Topline Results from a Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus | Biogen
Biogen to Present Data from Alzheimer’s Disease Portfolio at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting | Biogen
IMRALDI™, Biogen’s Adalimumab Biosimilar Referencing Humira®, Is Launched in the European Union | Biogen

Biogen on Wikipedia, Google News & Yahoo Finance

Biogen on LinkedIn, Twitter & YouTube

Biogen has 8 subsidiaries including Biogen Australia, Biogen Canada and Biogen Europe. Biogen has 1,300 competitors including Aldeyra Therapeutics (United States (USA)), Accera (United States (USA)) and Janssen Research & Development (United States (USA)).

Contact by email its executives including Stelios Papadopoulos

Call Biogen at +1 781....

View the org chart

Register to receive your alert

Report an error